Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/06/2018|
|Rapid review completed||21/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care|
|Full pharmacoeconomic assessment commissioned by HSE||27/06/2018|
|Pre submission consultation with Applicant||14/08/2018|
|Submission received from Applicant||09/01/2019|
|Preliminary review sent to Applicant||21/03/2019|
|NCPE assessment re-commenced||23/04/2019|
|Factual accuracy sent to Applicant||19/07/2019|
|NCPE assessment re-commenced||26/07/2019|
|NCPE assessment completed||14/08/2019|
|NCPE assessment outcome||The NCPE recommends that niraparib (Zejula®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.